BioCryst Pharma (BCRX) Tops Q3 EPS by 8c

BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.12), $0.08 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.11 million.

Cash, cash equivalents and investments totaled $127.6 million at September 30, 2014, compared to $40.8 million at December 31, 2013. This significant increase in cash and investments resulted from the Company's successful June public offering of common stock.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• BioCryst to close Birmingham lab and shift to external R&D model
• Magnificent 7 stocks lose $2.3 trillion in June